Press Release | Setting a New Benchmark in Functional Barrier Analysis
Dynamic42 expands its DynamicOrgan® System with fully integrated electrical resistance monitoring for advanced in vitro models.
Jena, 18.03., 2026 Dynamic42 GmbH announces the launch of the DynamicOrgan® TEER-Sensor Kit & System, enabling integrated Trans-Epithelial/Trans-Endothelial Electrical Resistance (TEER) measurement within its Organ-on-Chip platform. The new solution embeds electrical resistance monitoring directly into the DynamicOrgan® biochip architecture and will be officially presented at the SOT 2026 Annual Meeting after becoming commercially available on March 18, 2026. With this release, Dynamic42 advances cellular barrier analysis from an external time-dependent to an intrinsic/real-time measurement within microphysiological systems.
The integrity of cellular barriers is a fundamental characteristic of tissues such as intestine, lung, skin, and the blood–brain barrier, which is essential for maintaining compartmentalization and homeostasis. While resistance measurement has long been the established method to assess intercellular junction dynamics and tissue permeability, conventional approaches were developed for static insert systems rather than for dynamically perfused microenvironments.
Dynamic42 has redesigned this principle specifically for Organ-on-Chip applications. Gold electrodes are embedded within the upper and lower bonding layers of the proven 2-channel biochip. An alternating current is applied across the cultured tissue, and the resulting resistance is detected and measured via the tighTEER T-31 readout unit.
This fully integrated design eliminates external electrode handling, ensures standardized geometry, and delivers highly reproducible measurements under physiological flow conditions. Because the electrodes are semi-transparent, light microscopic imaging remains fully accessible.
The measured resistance becomes a real-time indicator of tissue barrier performance. Increasing resistance corresponds to intact intercellular junctions and a functional cell barrier, while decreasing values indicate functional impairment. What were previously static endpoint measurements become real-time and non-invasive monitoring within a physiological microenvironment.
Turning Barrier Monitoring into Real-Time Functional Insight
By embedding resistance monitoring directly into the platform, Dynamic42 enables assessment of barrier status throughout the entire experimental timeline. Tissue maturation, compound-induced disruption, and recovery dynamics can be tracked without interfering with the system.
Toxicology applications benefit from earlier detection of substance-induced barrier damage under physiologically relevant exposure conditions. For pharmaceutical development, the platform enhances permeability assessment and model validation by delivering quantitative data under flow. Academic researchers gain a robust tool to investigate intercellular junction dynamics and barrier integrity upon inflammatory conditions, microbiota co-culture, and pharmaceutical compound administration among numerous research applications.
From Service Expertise to Scalable Product Solution
Dynamic42 first implemented integrated resistance monitoring within its Fee-for-Service portfolio in 2025. With the introduction of the new kit and systems, this capability is now available as a standardized product for customer laboratories worldwide.
“Our goal was simple: stop adapting old measurement concepts to microfluidics and start engineering them for it,” says Tim Kaden, Field Applications Specialist at Dynamic42. “We integrated electrical barrier monitoring where it belongs: inside the chip.”
With the DynamicOrgan® TEER-Sensor Kit & System, Dynamic42 reinforces its position as a technology leader in Organ-on-Chip platforms, delivering solutions that address the growing demand for predictive, quantitative, and application-driven in vitro models.
Royalty-free images for free use here.
About Dynamic42
Dynamic42 GmbH was founded in 2018 and is a spin-off from the Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) of the University Hospital Jena. Dynamic42 markets and develops human organ-on-chip models/ microphysiological systems with integrated immune system components for research and testing of pharmaceutical products, novel therapies such as nanoparticles, chemical and food additives.
Media Contact:
Dr. Juliane Fischer
PR Management
Dynamic 42 GmbH
Winzerlaer Straße 2
07745 Jena
Phone +49 3641 508101